NICE does not recommend apremilast
The National Institute for Health and Care Excellence (NICE) does not recommend apremilast (Otezla; Celgene) for treating some adults with moderate to severe chronic plaque psoriasis.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200194
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com